Huang Peiying, Li Zhishang, Chen Li, Zeng Jing, Zhao Shuai, Tang Yong, Huang Bixuan, Guan Hansu, Chen Yan, Feng Yuchao, Lei Sisi, Wu Qihua, Zhang Haobo, Huang Xiaoyan, Zeng Linsheng, Liu Yuxiang, Zeng Zhongyi, Chen Bojun
The Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
Emergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.
Front Pharmacol. 2022 Aug 17;13:918689. doi: 10.3389/fphar.2022.918689. eCollection 2022.
Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical Trials.gov, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results. URL = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534, CRD 42022316534.
稳定型心绞痛是一种发病率和死亡率都很高的常见病症。据报道,口服中成药(OCPMs)与西药(WM)联合使用可能比单独使用西药取得更好的效果。然而,用于稳定型心绞痛的最佳中成药仍存在争议,值得进一步的实证研究。检索了PubMed、Embase、Web of Science、Cochrane图书馆、Ovid-Medline、ClinicalTrials.gov、中国知网、万方数据库、维普期刊数据库和中国生物医学文献数据库,检索时间从建库至2022年3月13日。我们使用Cochrane偏倚风险工具(ROB2)第2版来评估所选研究的整体质量。我们还使用R 4.1.2和STATA 14.0软件进行网络荟萃分析,随后进行敏感性和亚组分析。共纳入179项随机对照试验,涉及16789例患者。所选试验均被评估为存在一些问题。中成药与西药联合使用比单独使用西药具有更好的治疗效果。在有效临床率方面,与参松养心胶囊(SSYX)+西药、麝香保心丸(SXBX)+西药、通心络胶囊(TXL)+西药、血府逐瘀胶囊(XFZY)+西药、芪苈强心胶囊(QLQX)+西药、脑心通胶囊(NXT)+西药、复方丹参滴丸(FFDS)+西药和丹蒌片(DL)+西药相比,发现芪参益气滴丸(QSYQ)+西药有显著提高。QSYQ +西药具有最高的排序概率(98.12%)。在心电图有效率方面,QSYQ +西药优于SXBX +西药、TXL +西药、DL +西药、FFDS +西药和NXT +西药。QSYQ +西药排名第一(94.21%)。在心绞痛每周发作频率方面,QLQX +西药比FFDS +西药、宽胸气雾剂(KXQW)+西药、NXT +西药、QLQX +西药、SSYX +西药、SXBX +西药和TXL +西药取得更好的效果。QLQX +西药排名第一(100.00%)。在心绞痛发作持续时间方面,KXQW +西药优于SSYX +西药;KXQW +西药排名第一(95.71%)。在每周硝酸甘油使用量方面,TXL +西药具有最高的排序概率(82.12%)。在心血管事件发生率方面,DL +西药效果最高(73.94%)。此外,SSYX +西药的药物不良反应发生率最低(1.14%)。中成药与西药联合使用具有更高的疗效。QSYQ +西药、QLQX +西药、KXQW +西药、TXL +西药、DL +西药、SSYX +西药和SXBX +西药值得进一步研究。SXBX +西药可能是临床疗效和心血管事件发生率方面的最佳治疗方剂。需要进一步高质量的实证研究来证实当前结果。网址 = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534,CRD 42022316534